Frankfurt (Reuters) – The German group Merck KGAA announced on Monday that it had concluded an agreement to acquire the American Biotechnology SpringWorks Therapeutics for an amount of $ 3.9 billion (3.44 billion euros) in order to strengthen its activities in the field of anti -cancer treatment.
The company based in Darmstadt, Germany, said that the purchase price of 47 dollars per day was a net value of approximately $ 3.9 billion, a business value of $ 3.4 billion, after deduction of SpringWorks liquidity.
Last week, Merck KGAA said that the two companies were in the final trading of negotiations for a buy -back offer of around 47 dollars per share.
The acquisition will be funded by available liquidity and new debts. The German group said that the operation should have a positive effect on the benefit by corrected action of exceptional elements by 2027. Merck KGAA added that it would still be able to pursue larger transactions.
Springworks, based in Stamford, in Connecticut, has been listed on the New York Stock Exchange since 2019 and has specialized in the development of cancer treatments and rare tumors.
The company offers two products, Ogsiveo, with sales of $ 172 million in 2024 to treat desmoid tumors, and Gomekli, approved in February to treat NF1-PN, a nerve tumor disease.
(Report Ludwig Burger, Elena Smirnova, edited by Kate Entringer)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
